Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...
Nasdaq24d
Pliant Therapeutics Pauses Enrollment and Dosing in BEACON-IPF Phase 2b Trial Following DSMB Recommendation
The Company is actively monitoring the current patients in the BEACON-IPF trial, indicating a commitment to patient safety and well-being. Pliant Therapeutics is maintaining the integrity of the ...
Hosted on MSN11h
Pliant Therapeutics Reports Q4 2024 Results and Updates
Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...
Benzinga.com22d
Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues
Pliant Therapeutics paused enrollment in its BEACON-IPF Phase 2b trial of bexotegrast after a safety board review. Get 5 stock picks identified before their biggest breakouts, identified by the ...
Investing20h
Pliant Therapeutics shares rise on better-than-expected Q4 earnings
SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli ...
TipRanks on MSN15h
Ocular Therapeutix Reports 2024 Financial Results and Progress
Ocular Therapeutix Inc ( ($OCUL) ) has released its Q4 earnings. Here is a breakdown of the information Ocular Therapeutix ...
TMCnet2h
MassMutual Reports Strong 2024 Financial Results
"In a year with robust economic fundamentals and strong equity market performance, contrasted with rising costs of living and monetary and fiscal policy uncertainty, MassMutual enhanced its position ...